Clinical trial · Interventional
Venlafaxine for Hot Flashes After Breast Cancer
NCT00198250CI-TRIAL-00001781completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate Venlafaxine as a treatment option for hot flashes in breast cancer survivors. The goals of this study are to assess the effectiveness and toxicity of venlafaxine hydrochloride and identify the psychological, behavioral, and physical outcomes associated with relief of hot flashes in women following treatment for breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| venlafaxine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Assess the effectiveness venlafaxine hydrochloride versus placebo in alleviating hot flash frequency, severity, distress, and magnitude in women following treatment for breast cancer.
- timeFrame
- completed
Secondary outcomes (1)
- measure
- Identify the psychological, behavioral, and physical outcomes associated with relief of hot flashes in women following treatment for breast cancer.
- timeFrame
- completed
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * women at least 21 years of age * willing and able to provide informed consent * first time diagnosis of breast cancer * no other history of cancer * considered disease free at time of study enrollment * at least four weeks post-completion of surgery, radiation, and/or chemotherapy for non-metastatic cancer * experiencing daily hot flashes * desirous of treatment for hot flashes, but not concurrently using any other hot flash treatments * living within 60 miles of Indianapolis * able to read, write and speak English Exclusion Criteria: * current treatment with antidepressants for depression, neuropathic pain or hot flashes * diagnosis of metastatic breast cancer (stage IV) * treatment for hot flashes within the past four weeks, including (a) soy supplements; (b) botanicals, such as dong quai (Angelica sinensis), black cohosh, ginseng, gotu kola, licorice root, chaste tree, sage, or wild yam root; (c) vitamin E; or (d) prescription medications, such as clonidine hydrochloride or megestrol acetate.
References
Publications (1)
- RESULTCarpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, Johnson CS, Shelton RC. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007 Jan;12(1):124-35. doi: 10.1634/theoncologist.12-1-124. PMID 17227907